Contents

Article Outline

• Perspectives
• Featured Articles
• Association Pages

Back to Article Outline

Perspectives 

65 Disease-modifying therapies in Alzheimer’s disease

Stephen Salloway, Jacobo Mintzer, Myron F. Weiner, Jeffrey L. Cummings

80 Partnership between academia and industry for drug discovery in Alzheimer’s disease

Adrian J. Ivinson, Roger Lane, Patrick C. May, David A. Hosford, Maria C. Carrillo, Eric R. Siemers

89 New directions for frontotemporal dementia drug discovery

John Q. Trojanowski, Karen Duff, Howard Fillit, Walter Koroshetz, Jeff Kuret, Diane Murphy, Larry Refolo

94 Commentary on “New directions for frontotemporal dementia drug discovery.” Do we know enough to develop meaningful treatments for frontotemporal dementia?

Dale Schenk

96 Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): The first twenty years

Gerda G. Fillenbaum, Gerald van Belle, John C. Morris, Richard C. Mohs, Suzanne S. Mirra, Patricia C. Davis, Pierre N. Tariot, Jeremy M. Silverman, Christopher M. Clark, Kathleen A. Welsh-Bohmer, Albert Heyman

Back to Article Outline

Featured Articles 

110 2008 Alzheimer’s disease facts and figures

Alzheimer’s Association

134 Trends in the prevalence and mortality of cognitive impairment in the United States: Is there evidence of a compression of cognitive morbidity?

Kenneth M. Langa, Eric B. Larson, Jason H. Karlawish, David M. Cutler, Mohammed U. Kabeto, Scott Y. Kim, Allison B. Rosen

145 The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): Design and baseline characteristics

Roy W. Jones, Miia Kivipelto, Howard Feldman, Larry Sparks, Rachelle Doody, David D. Waters, Judith Hey-Hadavi, Andrei Breazna, Rachel J. Schindler, Harry Ramos, on behalf of the LEADe investigators

Back to Article Outline

Association Pages 

154 Alzheimer’s Association Update